Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business segments include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - Revenue composition is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - Southern Fund has a significant holding in Tiger Med through the Southern CSI Innovative Drug Industry ETF (159858), which held 163,000 shares in the fourth quarter, representing 2.86% of the fund's net value, making it the ninth largest holding [2][5]. - The ETF has generated a floating profit of approximately 413,900 CNY today and 528,000 CNY during the three-day increase [2][5]. - The Southern CSI Innovative Drug Industry ETF was established on March 12, 2021, with a current size of 324 million CNY. Year-to-date, it has experienced a loss of 7.1%, ranking 4816 out of 5563 in its category, while it has gained 8.26% over the past year, ranking 3387 out of 4429 [2][5].

Group 1 - Core viewpoint: Huadong Medicine (000963.SZ) reported its Q3 2025 results, highlighting significant institutional ownership and changes in shareholding among various funds and investors [1][2][3] Group 2 - As of October 27, 2025, 32 institutional investors held a total of 1.205 billion shares of Huadong Medicine, representing 68.71% of its total share capital [1] - The top ten institutional investors collectively held 67.93% of the shares, with an increase of 0.71 percentage points compared to the previous quarter [1] - In the public fund sector, 10 funds increased their holdings, while 8 funds reduced their holdings, with a decrease of 0.50% in the latter category [2] - One social security fund, the National Social Security Fund 112 Portfolio, reported a slight decrease in holdings [2] - In the insurance sector, one insurance company increased its holdings by 0.3%, while one new insurance investor was disclosed [3] - Foreign investment saw an increase from one foreign fund, Hong Kong Central Clearing Limited, with a rise of 0.69% in holdings [3]

Market Overview - The Shanghai Composite Index decreased by 0.4% to 3351.31 points, with a weekly high of 3394.03 points [1] - The Shenzhen Component Index fell by 0.75% to 10607.33 points, reaching a high of 10745.09 points [1] - The ChiNext Index dropped by 1.12% to 2128.21 points, with a peak of 2165.16 points [1] - Global indices also experienced declines, with the Nasdaq Composite down 2.59%, the Dow Jones Industrial Average down 0.96%, and the S&P 500 down 1.53% [1] ETF Market Performance - The median weekly return for stock ETFs was -0.5% [2] - The highest weekly return among scale index ETFs was 0.87% for the Ping An CSI A50 ETF [2] - The highest return in industry index ETFs was 2.41% for the China Southern CSI Pharmaceutical Health ETF [2] - The top-performing thematic index ETF was the Huatai-PB CSI Hong Kong-Shenzhen Innovative Drug Industry ETF, with a return of 4.1% [2] ETF Liquidity - Average daily trading volume for stock ETFs decreased by 10.5%, while average daily trading volume increased by 0.5% [7] ETF Fund Flows - The top five stock ETFs with the highest inflows included the Jiashi CSI A500 ETF with an inflow of 501 million yuan and the China Southern CSI A500 ETF with an inflow of 426 million yuan [9] - The top five stock ETFs with the highest outflows included the Southern CSI 500 ETF with an outflow of 557 million yuan and the E Fund ChiNext ETF with an outflow of 402 million yuan [10] ETF Financing and Margin Trading - The financing balance for stock ETFs decreased from 45.0861 billion yuan to 44.5767 billion yuan [12] - The highest financing buy amount was 521 million yuan for the Huaxia CSI Sci-Tech 50 ETF [12] ETF Market Size - The total size of the ETF market reached 38,072.59 billion yuan, an increase of 12.028 billion yuan from the previous week [15] - Stock ETFs accounted for 28,371.86 billion yuan, representing the largest category in the ETF market [15] ETF Issuance and Establishment - No new ETFs were issued last week, but 13 new ETFs were established, including the Xinhua CSI A50 ETF and the Huaxia Sci-Tech 50 ETF [18] Institutional Insights - Industrial trends in the innovative drug sector are becoming clearer, with expectations for better development opportunities in China [19] - By 2024, approximately 31% of large multinational pharmaceutical companies are expected to introduce innovative drug candidates from China, indicating a significant market potential for Chinese innovative drugs [19]